home / stock / gnca / gnca news

GNCA News and Press, Genocea Biosciences Inc. From 01/02/19

Stock Information
Company Name: Genocea Biosciences Inc.
Stock Symbol: GNCA
Market: NASDAQ
Menu
GNCA GNCA Quote GNCA Short GNCA News GNCA Articles GNCA Message Board
Get GNCA Alerts

News, Short Squeeze, Breakout and More Instantly...
GNCA - Dosing underway in Phase 1/2a study of Genocea's cancer vaccine candidate GEN-009; shares up 22%

Thinly traded nano cap Genocea Biosciences ( GNCA ) is up  22%  out of the gate this morning following its announcement that the first patients have been dosed in a Phase 1/2a clinical trial evaluating neoantigen cancer vaccine candidate GEN-009. More news on: Genocea Bioscie...
GNCA - Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the dosing of the first patients in its Phase 1/2a clinical trial testing the safety, immunogenicity,...

GNCA - Genocea Appoints Girish Aakalu, Ph.D., Chief Business Officer

CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the hiring of industry veteran Girish Aakalu, Ph.D., as its new Chief Business Officer. In this role,...

GNCA - Genocea Unveils Possible Mechanism for Tumor Resistance to Immunotherapy at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

ATLAS™-identified “inhibitory” neoantigens promote tumor growth in mouse model  ATLAS platform continues to differentiate versus in silico methods for true  neoantigen identification CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Genocea Bi...
GNCA - Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q3 2018 Results - Earnings Call Transcript

Genocea Biosciences, Inc. (GNCA) Q3 2018 Earnings Conference Call November 1, 2018, 09:00 ET Executives Paul Arndt - Head of IR and MD, Communications, LifeSci Advisors William Clark - President, CEO & Director Jessica Flechtner - Chief Scientific Officer Tom Davis - Chief ...

GNCA - Genocea Reports Third Quarter 2018 Financial and Operating Results

Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial enrolling patients Presenting novel findings at upcoming SITC conference Conference call today at 9:00 am ET CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharm...

GNCA - Genocea to Host Third Quarter 2018 Financial Results Conference Call & Webcast on November 1, 2018 at 9:00 a.m. ET

CAMBRIDGE, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, November 1, 2018 at 9:00...
GNCA - Analysis: Positioning to Benefit within Genocea Biosciences, Retail Properties of America, Hawkins, QUANTENNA COMMS, Hillenbrand, and Herman Miller - Research Highlights Growth, Revenue, and Consolidated Results

NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Genocea Biosciences, Inc. (NASDAQ:GNCA), Retail Properties of America,...

GNCA - Genocea Announces Upcoming Presentations at SITC 2018

Posters showcase ability of ATLAS™ platform to identify neoantigens for inclusion in and exclusion from personalized immunotherapies CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing persona...

GNCA - Genocea Strengthens Leadership Team: Thomas Davis, M.D. Appointed Chief Medical Officer; Derek Meisner, J.D. Joins as General Counsel

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced two additions to its leadership team: Thomas Davis, M.D. as Chief Medical Officer and Derek Meisner, ...
Previous 10 Next 10